The architecture functions as a conditional model that processes a million-letter DNA sequence alongside specific biological conditions to evaluate one cell state at a time. It captures subtle variations in specialized targets, such as heart muscle and blood immune cells, using extensive single-cell and bulk datasets. Furthermore, the system supports cross-modality imputation, enabling scientists to predict unmeasured features like chromatin accessibility from existing data.
Key points
The model evaluates DNA effects for individual tissues, cell types, or cell states rather…: The model evaluates DNA effects for individual tissues, cell types, or cell states rather than relying on tissue averages.
Cross-modality imputation allows scientists to prioritize lab experiments by inferring un…: Cross-modality imputation allows scientists to prioritize lab experiments by inferring unmeasured biological properties from single measurements.
The technology is accessible via an API for non-commercial research and is offered throug…: The technology is accessible via an API for non-commercial research and is offered through a private preview for commercial entities.
Sources checked by our analysis pipeline: 1
Our next-generation DNA sequence model bridges single-cell biology and human genetics, predicting how genetic variants affect hundreds of human cell types.
Today, we are announcing AlphaGenome 2, our next-generation model that predicts how DNA sequences and their variations impact specific human cell types, giving scientists a powerful new tool to uncover the cellular drivers of disease.
Cells are the building blocks of life. Every cell in our body carries the same DNA blueprint, yet each cell type and state—like a heart muscle cell or an immune cell fighting an infection—switches different genes on or off to do its job. Global efforts like the Human Cell Atlas are mapping this gene expression for millions of cells, but it is still an unsolved challenge to predict how subtle DNA variations affect this expression in cells, which is a key driver of human traits and disease.
Last year, we launched AlphaGenome to predict how DNA variants affect molecular activity across broad tissues. We expanded its reach with AlphaGenome Atlas, a platform containing predictions for all 9 billion possible single-letter changes in the human…
The cross-border startup is targeting the growing enterprise ecosystem by designing specialized analytics infrastructure tailored to autonomous digital software. This substantial launch capital allows the team to scale development across its dual headquarters in Israel and California. The move signals heightened investor appetite for back-end data architectures built expressly to serve next-generation artificial intelligence workflows.
Healthcare technology developers are increasingly pushing to ingest extensive patient records and administrative files to power broader clinical recommendations. This rapid transition from narrow, single-purpose functions to wide-ranging medical decision support challenges traditional clinical perspectives on data limitation. The shift marks an aggressive effort by digital health platforms to expand their operational footprints across patient care.
To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.